Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | Director | August 19, 2026 | August 27, 2026 |
| AbbVie Inc.ABBV · Entity 2800 | EVP, Chief Strategy Officer | May 16, 2022 | May 20, 2022 |
| Aptinyx Inc.APTX · Entity 120922 | Director | May 26, 2022 | May 31, 2022 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | Director · President & CEO | February 14, 2024 | February 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date August 19, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,662 |
Reported balance
After 2026-08-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-19 · Grant · Acquired 6,662 · Balance 6,662 F1: Represents a restricted stock award that will vest in three equal annual installments on the first, second and third anniversaries of August 19, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock award that will vest in three equal annual installments on the first, second and third anniversaries of August 19, 2026.
AbbVie Inc.
Report date May 16, 2022 · Filed May 20, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 41,623 |
Last balance in matching sequence
After 2022-05-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-05-16 · Exercise / conversion · Acquired 83,960 · Balance 125,583 Row 2 · 2022-05-16 · Sale · Disposed 83,960 · Balance 41,623 |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.86 · Expires 2026-02-17 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · 2022-05-16 · Exercise / conversion · Disposed 83,960 · Balance 0 F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectIn trust | 53,500 |
Reported balance
Holding disclosure · report date 2022-05-16 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance 53,500 F1: The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectProfit sharing trust | 3,638 |
Reported balance
Holding disclosure · report date 2022-05-16 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance 3,638 F2: Balance in AbbVie Savings program as of May 18, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.
F2: Balance in AbbVie Savings program as of May 18, 2022.
F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
Aptinyx Inc.
Report date May 26, 2022 · Filed May 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2032-05-25 | Direct | 40,000 |
Reported balance
After 2022-05-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-26 · Grant · Acquired 40,000 · Balance 40,000 F1: This option vests in ratable monthly installments over one year from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in ratable monthly installments over one year from the date of grant.
Neumora Therapeutics, Inc.
Report date February 14, 2024 · Filed February 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 462,345 |
Reported balance
After 2024-02-14 transaction · row 1
1 source rowRow 1 · 2024-02-14 · Grant · Acquired 80,000 · Balance 462,345 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.07 · Expires 2034-02-13 | Direct | 160,000 |
Reported balance
After 2024-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-14 · Grant · Acquired 160,000 · Balance 160,000 F4: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 15,000 |
Reported balance
Holding disclosure · report date 2024-02-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,000 F2: Shares held by HG4KYC TRUST, of which Reporting Person is trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 127,448 |
Reported balance
Holding disclosure · report date 2024-02-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 127,448 F3: Shares held by Lu Leng Felicia Chua Descendants 2012 Irrevocable Trust, of which Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.
F2: Shares held by HG4KYC TRUST, of which Reporting Person is trustee.
F3: Shares held by Lu Leng Felicia Chua Descendants 2012 Irrevocable Trust, of which Reporting Person is trustee.
F4: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACELYRIN, Inc.
Report date May 21, 2025 · Filed May 23, 2025
Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 92,158 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F2: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2033-03-22 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 155,450 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4: 1/48 of the shares subject to the option vested on April 17, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.
F2: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.
F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.
F4: 1/48 of the shares subject to the option vested on April 17, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 400 | $70.17 | $28,068.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 18 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,537 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 600 | $70.16 | $42,096.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 17 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,937 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 100 | $70.15 | $7,015.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 16 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,537 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 100 | $70.14 | $7,014.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 15 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,637 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 800 | $70.13 | $56,104.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 14 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,737 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 700 | $70.12 | $49,084.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 13 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,537 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 200 | $70.12 | $14,023.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 12 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,237 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,000 | $70.11 | $70,110.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 11 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,437 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 400 | $70.10 | $28,040.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 10 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,437 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 100 | $70.09 | $7,009.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 9 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,837 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 100 | $70.08 | $7,008.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 8 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,937 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 400 | $70.07 | $28,028.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 7 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,037 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 100 | $70.05 | $7,005.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 6 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,437 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 300 | $70.04 | $21,012.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 5 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,537 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 600 | $70.02 | $42,012.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,837 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,537 | $70.01 | $107,605.37 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,437 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 100 | $70.01 | $7,000.50 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,974 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 5,663 | $70.00 | $396,410.00 |
DisclosureSEC source: 0001179110-17-010982 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,074 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 200 | $70.45 | $14,090.00 |
DisclosureSEC source: 0001179110-17-010983 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,437 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 21:06 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, par value $0.01 | 100 | $70.37 | $7,037.00 |
DisclosureSEC source: 0001179110-17-010983 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,637 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 20,673 | $62.22 | $1,286,274.06 |
DisclosureSEC source: 0001179110-17-003702 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,737 Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:51 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 78,340 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002807 · edgar.xml · derivative · entry 4 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,340 Underlying: Common stock · 78,340 shares Expires 2027-02-15 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 26,114 on 02/16/2018, 26,113 on 02/16/2019, and 26,113 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:51 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 14,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002807 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,410 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:51 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 31,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002807 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,375 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| December 09, 2016 Filed Dec 9, 2016 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 13,871 | $60.90 | $844,743.90 |
DisclosureSEC source: 0001179110-16-032747 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,179 Read SEC document |
| February 18, 2016 Filed Feb 22, 2016 22:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 83,960 | $0.00 Strike: $54.86 | $0.00 |
DisclosureSEC source: 0001179110-16-019780 · edgar.xml · derivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,960 Underlying: Common stock · 83,960 shares Expires 2026-02-17 F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 27,987 on 02/18/2017, 27,986 on 02/18/2018, and 27,987 on 02/18/2019. Read SEC document |
| December 09, 2015 Filed Dec 11, 2015 22:22 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 64,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-016163 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,050 F2 · shares: A retention award of restricted stock granted under the AbbVie 2013 Incentive Stock Program. The award vests in annual increments of 21,514 on 12/09/2016, 21,513 on 12/09/2017, and 21,513 on 12/09/2018. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| December 09, 2015 Filed Dec 11, 2015 22:22 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 26,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-016163 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,510 F1 · shares: Performance vested restricted stock granted under the AbbVie 2013 Incentive Stock Program. The award has a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The award includes the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.